ID   P3HR-1
AC   CVCL_2676
SY   P 3 HR 1; P3HR1; P3HRI; P3HR1-BL; P3J HR-1; P3J-HR-1; P3JHR-1; P3JHR1; P3J HR1-K; P3J.HR1K; HR-1; HR1K; PO
DR   CLO; CLO_0008282
DR   CLO; CLO_0008331
DR   EFO; EFO_0002312
DR   CLDB; cl3837
DR   CLDB; cl5159
DR   CLDB; cl5242
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-2770
DR   ATCC; HTB-62
DR   BCRJ; 0338
DR   BioGRID_ORCS_Cell_line; 207
DR   BioSample; SAMN10987599
DR   cancercelllines; CVCL_2676
DR   Cell_Model_Passport; SIDM01254
DR   CGH-DB; 9199-4
DR   ChEMBL-Cells; CHEMBL3307242
DR   ChEMBL-Targets; CHEMBL612705
DR   CLS; 302310
DR   Cosmic; 724830
DR   Cosmic; 1517661
DR   Cosmic; 2822951
DR   DepMap; ACH-000707
DR   ECACC; 86010701
DR   GDSC; 1330988
DR   GEO; GSM887493
DR   GEO; GSM888575
DR   IARC_TP53; 177
DR   IGRhCellID; P3HR1
DR   IZSLER; BS TCL 99
DR   LiGeA; CCLE_098
DR   LINCS_LDP; LCL-2024
DR   PharmacoDB; P3HR1_1234_2019
DR   Progenetix; CVCL_2676
DR   PubChem_Cell_line; CVCL_2676
DR   Wikidata; Q54937282
RX   PubMed=170370;
RX   PubMed=327080;
RX   PubMed=913957;
RX   PubMed=1915267;
RX   PubMed=2052620;
RX   PubMed=2140233;
RX   PubMed=3518877;
RX   PubMed=4115493;
RX   PubMed=4122458;
RX   PubMed=4321017;
RX   PubMed=4321974;
RX   PubMed=4364259;
RX   PubMed=4912237;
RX   PubMed=4932228;
RX   PubMed=6231253;
RX   PubMed=6265077;
RX   PubMed=6278187;
RX   PubMed=6278188;
RX   PubMed=6286763;
RX   PubMed=8108117;
RX   PubMed=8344493;
RX   PubMed=8402660;
RX   PubMed=12068308;
RX   PubMed=12967475;
RX   PubMed=19358282;
RX   PubMed=20215515;
RX   PubMed=22460905;
RX   PubMed=25355872;
RX   PubMed=26589293;
RX   PubMed=28196595;
RX   PubMed=30285677;
RX   PubMed=30894373;
RX   PubMed=31068700;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: MYC genetic alteration cell panel (ATCC TCP-1035).
CC   Population: African; Nigerian.
CC   Doubling time: 17 hours (PubMed=8402660).
CC   HLA typing: A*03:01,03:01; B*58:01,58:01; C*04:01,04:01 (PubMed=26589293).
CC   HLA typing: A*03:01:01,74:01:01; B*53:01:01,58:01:01; C*04:01:01; DPB1*01:01:01,02:01:02; DQA1*01:02:01,05:05:01; DQB1*03:19:01,06:02:01; DRB1*11:02:01,15:03:01 (CLS=302310).
CC   Sequence variation: Mutation; HGNC; 7553; MYC; Simple; p.Pro72Ser (c.214C>T); ClinVar=VCV000012574; Zygosity=Unspecified (PubMed=8108117).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=12068308).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163His (c.487T>C); ClinVar=VCV000376680; Zygosity=Unspecified (PubMed=2052620; PubMed=8344493; PubMed=8402660).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu287Ter (c.859G>T); Zygosity=Unspecified (PubMed=2052620; PubMed=8344493; PubMed=8402660).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Omics: Deep exome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Omics: Virome analysis using RNAseq.
CC   Genome ancestry: African=97.8%; Native American=0%; East Asian, North=0.68%; East Asian, South=0%; South Asian=0%; European, North=0%; European, South=1.51% (PubMed=30894373).
CC   Derived from site: In situ; Ascites; UBERON=UBERON_0007795.
ST   Source(s): ATCC; CLS; ECACC
ST   Amelogenin: X (CLS; ECACC)
ST   Amelogenin: X,Y (ATCC)
ST   CSF1PO: 10,11
ST   D13S317: 12
ST   D16S539: 10,11
ST   D18S51: 12,19
ST   D19S433: 12,15
ST   D21S11: 28,36
ST   D2S1338: 21
ST   D3S1358: 16,17
ST   D5S818: 12
ST   D7S820: 8,10
ST   D8S1179: 14,15
ST   FGA: 23,24
ST   TH01: 7,9
ST   TPOX: 6,8
ST   vWA: 15,18,19 (CLS)
ST   vWA: 15,19 (ATCC; ECACC)
DI   NCIt; C27694; EBV-related Burkitt lymphoma
DI   ORDO; Orphanet_543; Burkitt lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1317 ! Jiyoye
SX   Male
AG   7Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 38
//
RX   PubMed=170370; DOI=10.1099/0022-1317-28-2-207;
RA   Adams A., Strander H., Cantell K.;
RT   "Sensitivity of the Epstein-Barr virus transformed human lymphoid cell
RT   lines to interferon.";
RL   J. Gen. Virol. 28:207-217(1975).
//
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
//
RX   PubMed=913957; DOI=10.20772/cancersci1959.68.3_357;
RA   Inada T., Kasuga T., Nojiri I., Hiraoka T., Furuse T.;
RT   "Comparative study on radiosensitivities of cultured cell lines
RT   derived from several human tumors under hypoxic condition.";
RL   Gann 68:357-362(1977).
//
RX   PubMed=1915267; DOI=10.1002/j.1460-2075.1991.tb07837.x;
RA   Farrell P.J., Allan G.J., Shanahan F., Vousden K.H., Crook T.;
RT   "p53 is frequently mutated in Burkitt's lymphoma cell lines.";
RL   EMBO J. 10:2879-2887(1991).
//
RX   PubMed=2052620; DOI=10.1073/pnas.88.12.5413;
RA   Gaidano G., Ballerini P., Gong J.Z., Inghirami G., Neri A.,
RA   Newcomb E.W., Magrath I.T., Knowles D.M., Dalla-Favera R.;
RT   "p53 mutations in human lymphoid malignancies: association with
RT   Burkitt lymphoma and chronic lymphocytic leukemia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:5413-5417(1991).
//
RX   PubMed=2140233; DOI=10.1111/j.1440-1827.1990.tb01549.x;
RA   Nakano A., Harada T., Morikawa S., Kato Y.;
RT   "Expression of leukocyte common antigen (CD45) on various human
RT   leukemia/lymphoma cell lines.";
RL   Acta Pathol. Jpn. 40:107-115(1990).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=4115493;
RA   Petit P., Verhest A., Lecluse van der Bilt F.A., Jongsma A.P.M.;
RT   "The chromosomes of the EB virus-positive Burkitt cell line P3J.HR1K
RT   studied by the fluorescent staining technique.";
RL   Pathol. Eur. 7:17-21(1972).
//
RX   PubMed=4122458; DOI=10.1002/ijc.2910100108;
RA   Klein G., Dombos L., Gothoskar B.;
RT   "Sensitivity of Epstein-Barr virus (EBV) producer and non-producer
RT   human lymphoblastoid cell lines to superinfection with EB-virus.";
RL   Int. J. Cancer 10:44-57(1972).
//
RX   PubMed=4321017; DOI=10.1002/ijc.2910060315;
RA   Durr F.E., Monroe J.H., Schmitter R., Traul K.A., Hirshaut Y.;
RT   "Studies on the infectivity and cytopathology of Epstein-Barr virus in
RT   human lymphoblastoid cells.";
RL   Int. J. Cancer 6:436-449(1970).
//
RX   PubMed=4321974;
RA   Maurer B.A., Imamura T., Wilbert S.M.;
RT   "Incidence of EB virus-containing cells in primary and secondary
RT   clones of several Burkitt lymphoma cell lines.";
RL   Cancer Res. 30:2870-2875(1970).
//
RX   PubMed=4364259; DOI=10.1002/ijc.2910110210;
RA   Klein G., Dombos L.;
RT   "Relationship between the sensitivity of EBV-carrying lymphoblastoid
RT   lines to superinfection and the inducibility of the resident viral
RT   genome.";
RL   Int. J. Cancer 11:327-337(1973).
//
RX   PubMed=4912237; DOI=10.1128/JVI.1.5.1045-1051.1967;
RA   Hinuma Y., Konn M., Yamaguchi J., Wudarski D.J., Blakeslee J.R. Jr.,
RA   Grace J.T. Jr.;
RT   "Immunofluorescence and herpes-type virus particles in the P3HR-1
RT   Burkitt lymphoma cell line.";
RL   J. Virol. 1:1045-1051(1967).
//
RX   PubMed=4932228; DOI=10.1002/ijc.2910070214;
RA   Gergely L., Klein G., Ernberg I.;
RT   "The action of DNA antagonists on Epstein-Barr virus (EBV)-associated
RT   early antigen (EA) in Burkitt lymphoma lines.";
RL   Int. J. Cancer 7:293-302(1971).
//
RX   PubMed=6231253; DOI=10.1002/ijc.2910330407;
RA   Ehlin-Henriksson B., Klein G.;
RT   "Distinction between Burkitt lymphoma subgroups by monoclonal
RT   antibodies: relationships between antigen expression and type of
RT   chromosomal translocation.";
RL   Int. J. Cancer 33:459-463(1984).
//
RX   PubMed=6265077;
RA   Pizzo P.A., Chattopadhyay S.K., Magrath I.T., Del Giacco E.,
RA   Sherrick D., Gray T.;
RT   "Examination of Epstein-Barr virus and C-type proviral sequences in
RT   American and African lymphomas and derivative cell lines.";
RL   Cancer Res. 41:3165-3171(1981).
//
RX   PubMed=6278187; DOI=10.1093/jnci/68.2.179;
RA   Zeuthen J., Klein G., Ber R., Masucci G., Bisballe S., Povey S.,
RA   Terasaki P.I., Ralph P.;
RT   "Human lymphoma-lymphoma hybrids and lymphoma-leukemia hybrids. I.
RT   Isolation, characterization, cell surface markers, and B-cell
RT   markers.";
RL   J. Natl. Cancer Inst. 68:179-195(1982).
//
RX   PubMed=6278188; DOI=10.1093/jnci/68.2.197;
RA   Klein G., Zeuthen J., Ber R., Ernberg I.;
RT   "Human lymphoma-lymphoma hybrids and lymphoma-leukemia hybrids. II.
RT   Epstein-Barr virus induction patterns.";
RL   J. Natl. Cancer Inst. 68:197-202(1982).
//
RX   PubMed=6286763; DOI=10.4049/jimmunol.129.3.1336;
RA   Benjamin D., Magrath I.T., Maguire R.T., Janus C., Todd H.D.,
RA   Parsons R.G.;
RT   "Immunoglobulin secretion by cell lines derived from African and
RT   American undifferentiated lymphomas of Burkitt's and non-Burkitt's
RT   type.";
RL   J. Immunol. 129:1336-1342(1982).
//
RX   PubMed=8108117;
RA   Albert T., Urlbauer B., Kohlhuber F., Hammersen B., Eick D.;
RT   "Ongoing mutations in the N-terminal domain of c-Myc affect
RT   transactivation in Burkitt's lymphoma cell lines.";
RL   Oncogene 9:759-763(1994).
//
RX   PubMed=8344493; DOI=10.1096/fasebj.7.10.8344493;
RA   Bhatia K.G., Goldschmidts W., Gutierrez M.I., Gaidano G., Dalla-Favera R.,
RA   Magrath I.T.;
RT   "Hemi- or homozygosity: a requirement for some but not other p53
RT   mutant proteins to accumulate and exert a pathogenetic effect.";
RL   FASEB J. 7:951-956(1993).
//
RX   PubMed=8402660;
RA   O'Connor P.M., Jackman J., Jondle D., Bhatia K.G., Magrath I.T.,
RA   Kohn K.W.;
RT   "Role of the p53 tumor suppressor gene in cell cycle arrest and
RT   radiosensitivity of Burkitt's lymphoma cell lines.";
RL   Cancer Res. 53:4776-4780(1993).
//
RX   PubMed=12068308; DOI=10.1038/nature00766;
RA   Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S.,
RA   Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N.,
RA   Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J.,
RA   Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S.,
RA   Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S.,
RA   Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J.,
RA   Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A.,
RA   Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T.,
RA   Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R.,
RA   Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.;
RT   "Mutations of the BRAF gene in human cancer.";
RL   Nature 417:949-954(2002).
//
RX   PubMed=12967475; DOI=10.1111/j.1349-7006.2003.tb01518.x;
RA   Maesako Y., Uchiyama T., Ohno H.;
RT   "Comparison of gene expression profiles of lymphoma cell lines from
RT   transformed follicular lymphoma, Burkitt's lymphoma and de novo
RT   diffuse large B-cell lymphoma.";
RL   Cancer Sci. 94:774-781(2003).
//
RX   PubMed=19358282; DOI=10.1002/ijc.24351;
RA   Inagaki A., Ishida T., Yano H., Ishii T., Kusumoto S., Ito A., Ri M.,
RA   Mori F., Ding J.-M., Komatsu H., Iida S., Ueda R.;
RT   "Expression of the ULBP ligands for NKG2D by B-NHL cells plays an
RT   important role in determining their susceptibility to
RT   rituximab-induced ADCC.";
RL   Int. J. Cancer 125:212-221(2009).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25355872; DOI=10.1128/JVI.02570-14;
RA   Cao S.-B., Strong M.J., Wang X., Moss W.N., Concha M., Lin Z.,
RA   O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.;
RT   "High-throughput RNA sequencing-based virome analysis of 50 lymphoma
RT   cell lines from the Cancer Cell Line Encyclopedia project.";
RL   J. Virol. 89:713-729(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//